A new study in the UK has found that Oxford AstraZeneca vaccines, manufactured and administered in India under the trade name Covishield, provide protection that can last a lifetime.
According to the study, the vaccine not only generated antibodies against the SARS-COV-2 virus, but also created “training camps” in the body, to allow T cells to seek out and destroy even kill. new variants.
As The Sun reports, the study’s authors are scientists from Oxford, the UK and Switzerland. who published in the journal Nature that anti-adenovirus vaccines like those developed by Oxford AstraZeneca and Johnson & Johnson can cause the body to continue making vital T cells even long after the antibodies from the injected vaccine have disappeared. They say that maybe it could continue to make them for life.
“The T cells that come from these cellular training camps appear to have a very high level of ‘fitness’,” said Professor Burkhard Ludewig, a researcher at the Cantonal Hospital in Switzerland. He continues, “Adenoviruses have co-evolved with humans over a very long time, and I’ve learned a lot about the human immune system in the process.
According to the results of the study, adenoviruses have the ability to enter long-lived tissue cells. These cells, called fibroblast reticular cells, can act as “training grounds” for T lymphocytes.
The new findings add weight to recent studies that showed the Oxford AstraZeneca vaccine to be more effective at generating T cells than Pfizer and Moderna, both of which are mRNA vaccines.
According to Professor Paul Klenerman, of the Nuffield Department of Medicine, Oxford, said: “Millions of people have been vaccinated against adenoviruses around the world. The ultimate goal of these vaccines is to induce long-term protection of the immune system using both antibodies and T cells. This research helps us to better understand the vaccination process and why the effects on them. Killer T cells are so prolonged. “